Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiozyme in Metastatic Renal Cell Cancer
NCT00021021Phase 2Completed
- Sponsor
- Ribozyme Pharmaceuticals
- Start
- Sep 2001
- Modality
- RNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of angiozyme in renal cell carcinoma (RCC), sponsored by Ribozyme Pharmaceuticals. Primary endpoint: Response Rate. Started Sep 2001; status: completed.
02
Drugs
angiozyme
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00021021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021021.